Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)

Autor: Kwee L. Yong, Samantha Hinsley, Holger W. Auner, Ceri Bygrave, Martin F. Kaiser, Karthik Ramasamy, Ruth M. de Tute, Debbie Sherratt, Louise Flanagan, Mamta Garg, Stephen Hawkins, Catherine Williams, Jamie Cavenagh, Neil K. Rabin, James Croft, Gareth Morgan, Faith Davies, Roger G. Owen, Sarah R. Brown

Publikováno v: Haematologica, Vol 106, Iss 10 (2021)

The proteasome inhibitors, carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these proteasome inhibitors in combination with cyclophosphamide and d

Externí odkaz: https://doaj.org/article/ba5b64df09aa40b1b00ecd0bd0337518

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

Autor: Meral Beksac, Simona Iacobelli, Linda Koster, Jan Cornelissen, Laimonas Griskevicius, Neil K. Rabin, Anne Marie Stoppa, Ellen Meijer, Jean-Baptiste Mear, Sacha Zeerleder, Jiri Mayer, Roland Fenk, Nathalie Fegueux, Patrice Chevallier, Eva Konirova, John A. Snowden, Monika Engelhardt, Kim Orchard, Cyrille Hulin, Nicolaas Schaap, Claudia Sossa, Ahmet Elmaagacli, Donal P. McLornan, Patrick J. Hayden, Stefan Schönland, Ibrahim Yakoub-Agha

Publikováno v: Bone Marrow Transplantation. Nature Publishing Group
Beksac, M, Iacobelli, S, Koster, L, Cornelissen, J, Griskevicius, L, Rabin, N K, Stoppa, A M, Meijer, E, Mear, J-B, Zeerleder, S, Mayer, J, Fenk, R, Fegueux, N, Chevallier, P, Konirova, E, Snowden, J A, Engelhardt, M, Orchard, K, Hulin, C, Schaap, N, Sossa, C, Elmaagacli, A, McLornan, D P, Hayden, P J, Schönland, S & Yakoub-Agha, I 2023, ' An early post-transplant relapse prediction score in multiple myeloma : a large cohort study from the chronic malignancies working party of EBMT ', Bone Marrow Transplantation . https://doi.org/10.1038/s41409-023-01999-1

Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43fb4c1e1c34a89ee68a56aa14fdcf34
https://pure.eur.nl/en/publications/a0b2dfef-0ebe-45fa-8fa3-a0858599ba8f

Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)

Autor: Sotirios Bristogiannis, Yadanar Lwin, Catherine SY Lecat, Joanne Sowter, Orla McCourt, Emma Dowling, Nuno Correia, Neil K Rabin, Ke Xu, Jonathan Sive, Xenofon Papanikolaou, Rakesh Popat, Lydia Lee, Annabel McMillan, Sosana Delimpasi, Ashutosh D. Wechalekar, Kwee Yong, Charalampia Kyriakou

Publikováno v: Blood. 140:12506-12507

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7901723be9f6a6d27b250fcc915c642a
https://doi.org/10.1182/blood-2022-167272

Improved response with post- ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma.

Autor: Rabin, Neil, Percy, Laura, Khan, Iftekhar, Quinn, John, D'Sa, Shirley, Yong, Kwee L.

Publikováno v: British Journal of Haematology; Aug2012, Vol. 158 Issue 4, p499-505, 7p, 2 Charts, 2 Graphs